



# United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/647,739	08/25/2003	Manuel Guzman Pastor	A34700 PCT USA-I	2301	
21003 75	90 01/05/2006		EXAMINER		
BAKER & BOTTS			COOK, REBECCA		
30 ROCKEFEL NEW YORK, 1		ART UNIT	PAPER NUMBER		
			1614		
			DATE MAIL ED: 01/05/2004	4	

DATE MAILED: 01/05/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

		Applicati	on No.	Applicant(s)			
Office Action Summary		10/647,7	39	GUZMAN PASTOR ET AL.			
		Examine	7	Art Unit	]		
		Rebecca	Cook	1614			
Period fo	The MAILING DATE of this communica r Reply	tion appears on the	e cover sheet v	with the correspondence ac	ddress		
A SHO WHIC - Exter after - If NO - Failur Any r	DRTENED STATUTORY PERIOD FOR HEVER IS LONGER, FROM THE MAII sions of time may be available under the provisions of 3 SIX (6) MONTHS from the mailing date of this communication period for reply is specified above, the maximum statutor to to reply within the set or extended period for reply will eply received by the Office later than three months after the digital patent term adjustment. See 37 CFR 1.704(b).	LING DATE OF THE ST CFR 1.136(a). In no everation. ory period will apply and work by statute, cause the apply and work apply a	HIS COMMUN rent, however, may a rill expire SIX (6) MC olication to become A	IICATION.  The reply be timely filed  ONTHS from the mailing date of this of the case of this case.  ABANDONED (35 U.S.C. § 133).			
Status							
2a) <u></u> □	Responsive to communication(s) filed of This action is <b>FINAL</b> . 2b) Since this application is in condition for closed in accordance with the practice	D⊠ This action is r rallowance except	non-final. : for formal ma		e merits is		
Dispositi	on of Claims						
5)□ 6)⊠ 7)□	Claim(s) <u>16</u> is/are pending in the applicate (4a) Of the above claim(s) is/are Claim(s) is/are allowed. Claim(s) <u>16</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction	withdrawn from co					
Applicati	on Papers						
9)[	The specification is objected to by the E	Examiner.					
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	nder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  a) All b) Some * c) None of:  1. Certified copies of the priority documents have been received.  2. Certified copies of the priority documents have been received in Application No  3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.							
2) Notic 3) Infor	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTC nation Disclosure Statement(s) (PTO-1449 or PT r No(s)/Mail Date		Paper No	v Summary (PTO-413) o(s)/Mail Date f Informal Patent Application (PT 	<sup>-</sup> O-152)		

Application/Control Number: 10/647,739 Page 2

Art Unit: 1614

#### **DETAILED ACTION**

Claim 16 is pending and examined.

Applicants are again requested to clarify the continuing data. The data provided by them is not consistent with PTO records.

### Claim Rejections - 35 USC § 112 Paragraph One

Claim 16 is again rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. CANCERLIT AN 75803230 (abstract) discloses that not all of the cannabinoids recited in claim 16 have cytoxic activity against malignant tumors.

Applicants have presented data that demonstrates the effectiveness of .delta.9-tetrahydrocannabinol (THC) against glioblastoma cells, but have not presented any data that demonstrates the effectiveness of any of the claimed cannabinoids against any of the recited brain tumors.

Applicants argue that the effectiveness of the recited cannabinols is supported by the effectiveness of .delta.9.-tetrahydrocannabinol, since all of the claimed compounds are very closely structurally related. This is not persuasive. .Delta.9.-tetrahydrocannabinol and .delta.8.-tetrahydrocannabinol are closely related, differing only by the position of a double bond. However, cannabinol is a dibenzo compound and cannabidiol has two rings, but is not a 3-cyclo compound.

Claim Rejections - 35 USC § 112 Paragraph Two

Art Unit: 1614

Claim 16 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The recitation of the plural "glioblastomas" in claim 16 is confusing, since it requires that the mammal have more than one tumor. Amending it to recite "one or more glioblastomas" will overcome this rejection.

In view of applicants' amendment to the claim the earlier rejection under 35 USC 112, paragraph two is withdrawn.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(a) the invention was known or used by others in this country, or patented or described in a printed publication in this or a foreign country, before the invention thereof by the applicant for a patent.

Claim 16 is rejected under 35 U.S.C. 102(a) as being anticipated by Galve-Roperh et al.

Galve-Roperh et al (abstract) discloses that .delta.9.-tetrahydrocannabinol a induces regression of malignant gliomas and would be useful to treat them.

#### Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner Cook whose telephone number is (571) 272-0571. The examiner can normally be reached on Monday through Thursday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low, can be reached on (571) 272-0951.

Art Unit: 1614

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Renee Jones (571) 272-0547 in Customer Service.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

The official fax number is 571-273-8300.

Rebecca Cook

Mullealn M

Primary Examiner
Art Unit 1614

January 3, 2006